It inhibits human type II 5a-reductase (present in the hair follicle) with a selectivity 100 times greater than human type I 5a-reductase, and blocks the peripheral conversion of testosterone to dihydrotestosterone.
Treatment of the 1st phases of androgenetic alopecia in men, and stabilizes the process in men aged 18-41 years. Proviron Capsules
To access the dosage information on Vademecum.es you must log in with your email and password or register.Log in Register Oral: 1 mg/day, with or without food.Topical: Depending on the size of the bald spot, 1 to 4 non-overlapping sprays (50 to 200 microliters of solution) can be used once a day on bald areas of the scalp.
To access the dosage information on Vademecum.es you must log in with your email and password or register.
Oral: 1 mg/day, with or without food.Topical: Depending on the size of the bald spot, 1 to 4 non-overlapping sprays (50 to 200 microliters of solution) can be used once a day on bald areas of the scalp.
Oral.Take with or without food.Cutaneous use.It should only be used on the scalp.
Women.Finesteride hypersensitivity.Women who are pregnant or may become pregnant.
The safety and effectiveness of this medication in children and adolescents under 18 years of age have not been established.Decreases serum PSA.Risk of external genital malformations in male fetuses (avoid handling crushed or broken tablets).Risk of breast cancer in men.Mood alterations and depression, monitor for psychiatric symptoms and if these occur, interrupt treatment.Risk of systemic adverse reactions of a sexual nature related to the decrease in testosterone to dihydrotestosterone, although less likely in the case of the topical form than in the case of oral finasteride.Respect the dosage schedule.
Caution.It has not been studied.
It is not necessary to adjust the dosage in patients with renal failure.
Although the risk of finasteride affecting the pharmacokinetics of other substances is estimated to be low, cytochrome P450 3A4 inhibitors and inducers are likely to affect the plasma concentration of finasteride.However, based on established safety margins, any increase due to simultaneous administration of such inhibitors is unlikely to be of clinical significance.
The use of finasteride is contraindicated in women due to the risk involved in pregnancy.Due to finasteride's ability to inhibit the conversion of testosterone to dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of male fetuses if administered to pregnant women.
It is not indicated for women.It is unknown if it is excreted in breast milk.
Topical use: pruritus, erythema;decrease in dihydrotestosterone.Oral route.Other adverse reactions identified after evaluation of pharmacovigilance data: anxiety.
©Vidal Vademecum Source: The content of this monograph on the active ingredient according to the ATC classification has been written taking into account the clinical information of all medicines authorized and marketed in Spain classified in said ATC code.To know in detail the information authorized by the AEMPS for each medication, you must consult the corresponding Technical Sheet authorized by the AEMPS.
To access pricing information you must log in with your email and password or register.
To access pricing information you must log in with your email and password or register.
To access pricing information you must log in with your email and password or register.
To access pricing information you must log in with your email and password or register.
To access pricing information you must log in with your email and password or register.
To access pricing information you must log in with your email and password or register.
Anavar For Cutting © Vidal Vademecum Spain |Cochabamba, 24. 28016 Madrid, Spain - Tel. 91 579 98 00 - Fax: 91 579 82 29 Vademecum.es is officially recognized by the corresponding health authorities as Valid Support to include advertising of prescription drugs or pharmaceutical specialties aimed at professionals health (SVnº09/10-W-CM), granted on December 3, 2010. Notice: The information contained on this website is aimed exclusively at the professional intended to prescribe or dispense medications, which requires specialized training for its use. correct interpretation.© Vidal Vademecum Spain |Contact us |Privacy Policy |Legal notice |Cookies Policy |Configure Cookies preferences